Lewisville Rehabilation is categorized under Sports Medicines in Lewisville, TX and active since 1990.
Lewisville Rehabilation was established in 1990, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Sports Medicines business, which does work in the B2C market, and is classified as a Sports Medicines, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Ashley Mcclellan at the company’s single location by writing to 500 West Main St, Lewisville, Texas TX 75057 or by phoning (972) 420-1775. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lewisville Rehabilation |
| Contact Person: | Ashley Mcclellan |
| Address: | 500 West Main St, Lewisville, Texas 75057 |
| Phone Number: | (972) 420-1775 |
| Website Address: | lewisvillemedical.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 1990 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Sports Medicines |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Lewisville Rehabilation was started in 1990 to provide professional Sports Medicines under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Ashley Mcclellan for inquiries that concern Lewisville Rehabilation by calling the company number (972) 420-1775, as your correspondence is most welcome. Additionally, the physical location of the single location of Lewisville Rehabilation can be found at the coordinates 33.046142,-97.004999 as well as the street address 500 West Main St in Lewisville, Texas 75057.
For its online presence, you may visit Lewisville Rehabilation’s website at lewisvillemedical.com and engage with its social media outlets through on Twitter and on Facebook.